

Date and Time: 10th of December 2010, 10 am to 4 pm

Minutes: Confirmed

Guideline Development Group Meeting 5 Acute Upper GI Bleeding Guideline
Place: Boardroom, National Clinical Guideline Centre, 180 Great
 Portland Street, London W1W 5QZ

Present

GDG

1. Kelvin Palmer	KP
2. Kenneth Halligan	KH
3. Mimi McCord	MM
4. David Patch	DP
5. Mark Donnelly	MD
6. Simon McPherson	SM
7. Dan Greer	DG
8. Markus Hauser	MH
9. Carlos Gomez	CG
10. Joseph Varghese	JV
11. Mark Vaughan	MV

NICE / NCGC

12. Bernard Higgins	BH
13. Katharina Dworzynski	KD
14. Lina Gulhane (pm only)	LG
15. Panos Kefalas	PK
16. Philippe Laramée	PL
17. Sarah Dunsdon	SD
18. Stephen Atkinson	SA

Co-optees

19. Mike Murphy	MM
20. Vipul Jairath	VJ

Apologies

1. Ricky Forbes Young	RF
-----------------------	----

Notes

1. Introduction Formalities

The Chair (KP) welcomed attendees to the Acute Upper GI Bleeding (UGIB) guideline development group (GDG) meeting 5 and asked all GDG members to declare any relevant conflicts of interest.

KP, MM and VJ declared their non-personal pecuniary interest arising from applying for a research grant to investigate blood transfusion requirements of patients with Upper GI Bleeding.

Notes

All other GDG members declared that they had no personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role).

Then the minutes, and LETR of the last meeting of this group were agreed as a true and accurate account of the meeting.

Subsequently, the Chair briefed the group on the objectives of the GDG meeting 5.

2. **Update on HE Analysis on “Timing of Endoscopy”**

PL presented progress with respect to the development of the in-house health-economic (HE) model that assesses the cost-effectiveness of the “timing of endoscopy”. The GDG discussed the inputs into the model and agreed next steps.

3. **Evidence Review for blood transfusion requirements of patients with Upper GI Bleeding:**

KD first presented the evidence available on the identification of the most clinically effective threshold and target level at which red blood cell transfusions should be administered to improve outcome in patients with UGIB and low level of haemoglobin. She then continued with presenting the evidence available on the most clinically effective threshold and target level at which platelets and clotting factors should be administered to improve outcome in patients with UGIB and low platelet count and/or abnormal coagulation factors.

PL then presented HE evidence on the same topics which supported the use of red blood cells, platelets and fresh frozen plasma transfusions in UGIB patients on the grounds of cost-effectiveness. However the use of recombinant factor VIIa in UGIB patients with variceal bleeding was shown not to be cost-effective as the ICER exceeded the NICE threshold.

The GDG agreed that there were limitations with the current evidence base. Therefore the GDG leveraged its professional experience together with the evidence presented and drafted consensus recommendations.

4. **Review protocols:**

KD and LG presented and obtained agreement from the GDG on the Review Protocols for clinical questions related to “Repeat endoscopic treatment “

Date, time and venue of the next meeting

The next GDG meeting will take place on the 28th of January, 2011 from 10 am to 4 pm, at the National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ